Clinical trials: Sitagliptin
Diabetes Mellitus, Type 2, Obesity
Role of Interleukin-6 in Exercise
The purpose of the study is to understand the role of interleukin-6 during physical activity in patients with type 2 diabetes.
- Trial name
- Exil-6 (NCT01073826)
- Testing
- Sport, Tocilizumab, Sitagliptin
- Where
- Switzerland
- Volunteers
- 56 people
- Sponsor
- University of Zurich
Type 2 Diabetes
Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)
To evaluate the effect of treatment with sitagliptin compared to placebo in elderly patients with type 2 diabetes mellitus who have poor glycemic control with diet and exercise.
- Trial name
- NCT00305604
- Testing
- sitagliptin phosphate
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Microvascular Dysfunction
Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults
GLP-1 is an agent for treatment of type 2 diabetes and may have protective effects on the cardiovascular system. The mechanism is complex and there seems to be a dual function with intact GLP-1 (7-36), acting through the GLP-1…
- Trial name
- NCT02333591
- Testing
- GlucagonLikePeptide-1 (7-36), GlucagonLikePeptide-1 (9-36), Saline
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Mette Zander
Type 2 Diabetes
Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose
The aim of the study is to compare the FGM glycemic profiles in patients with type 2 diabetes mellitus treated with sitagliptin and acarbose.
- Trial name
- NCT05035849
- Testing
- sitagliptin and acarbose
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
- Trial name
- NCT03602638
- Testing
- Sitagliptin, Acarbose
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Type 2 Diabetes, Microalbuminuria
Use of Sitagliptin to Decrease Microalbuminuria
The people being asked to participate in this study have type 2 diabetes and abnormal levels of protein in their urine. This indicates that they are starting to develop diabetic kidney disease.
- Trial name
- NCT02048904
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Missouri-Columbia
Diabetes Mellitus, Type 2
Glucagon-like Peptide (GLP) Utilization and Safety
This study will assess the utilization patterns (adherence, source of the index antidiabetic agent (ADA) and treatment modification) of the marketed glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide)…
- Trial name
- NCT01767389
- Testing
- The GLP-1 receptor agonist users, DPP-4 inhibitor users, Other ADA users
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
This is an observational study to compare the effectiveness of dual therapy of Type II diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine clinical practice in France.
- Trial name
- NCT01357135
- Testing
- Metformin, Sitagliptin, Sulfonylurea
- Volunteers
- 3,453 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid19, Diabetes Mellitus, Type 2
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
The COVID-19 pathology is frequently associated with diabetes mellitus and metabolic syndrome. In the epidemic outbreak that exploded at the beginning of 2020 in the Lombardy Region, about two thirds of the patients who died from…
- Conditions
- Covid19, Diabetes Mellitus, Type 2, CKD
- Trial name
- SIDIACO (NCT04365517)
- Testing
- Sitagliptin
- Where
- Italy
- Volunteers
- 170 people
- Sponsor
- University of Milan
Diabetes, Diabetes Mellitus, Type 2
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
This trial is conducted in Asia, Europe, Oceania and South America. The aim of this clinical trial is to generate data demonstrating how to intensify diabetes treatment using BIAsp 30 (biphasic insulin aspart 30) by adding or…
- Trial name
- SIT2MIX (NCT01519674)
- Testing
- biphasic insulin aspart 30, sitagliptin, metformin
- Where
- 69 sites in Argentina, Australia and 8 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus.
- Trial name
- NCT01059825
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 375 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
The investigators set up a clinical trial to compare effect of dapagliflozin, a sodium glucose co-transporter 2 inhibitor, with gliclazide on vascular function in patients with type 2 diabetes
- Trial name
- NCT02610088
- Testing
- Dapagliflozin, Gliclazide
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Seoul National University Bundang Hospital
Diabetes After Total Pancreatectomy
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion
Glucagon is a 29-amino acid peptide hormone of essential importance for glucose homeostasis. Hitherto glucagon has been believed to be secreted only from the pancreas, but recent studies show that glucagon is also secreted from…
- Trial name
- Px-Meal (NCT04061473)
- Testing
- Sitagliptin 100mg, Empagliflozin 25 MG
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM.
- Trial name
- IMPERIUM (NCT02072096)
- Testing
- Glimepiride, Metformin, Pioglitazone
- Where
- 34 sites in United States, Austria and 3 more
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea